Skip to main
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is a leading healthcare company with a positive outlook, as it has developed a groundbreaking multi-cancer early detection blood test with the potential to detect all types of cancer. The company has strong financials and a competitive advantage in the underpenetrated $100B MCED market, with a projected revenue growth of 27% and a premium multiple justified. However, the company may face risks in reduced government funding and increased regulatory hurdles, as well as dependence on volatile emerging markets.

Bears say

GRAIL is facing major obstacles in its key data presentations this month, as NHS-Galleri missed its primary endpoint and the FDA is under iterative review. Sales have shown growth, but the company may struggle with the high cost of its multi-cancer early detection test and concerns over false confidence in missing early stage cancers. Financials appear strong, but future catalysts and study results may greatly impact GRAIL's success.

GRAIL Inc (GRAL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 8 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.